Tag: Novo Nordisk

All Podcast Categories
S2-E55 - Day Three at the 2021 TLM dX From AASLD

S2-E55 – Day Three at the 2021 TLMdX From AASLD

Profs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join Louise Campbell and Roger Green to review some of the most important and exciting presentations from the first three days of the 2021 TLMdX, the annual meeting from AASLD.

S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates

S2-E42.3 – Why FGFs Matter and Screen Fail Rate

Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGFs) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation detours into health policy and screen fail rates before returning to consider the 2-5 year implications of FGF drug therapies.

S2-E8 – Previewing NASH-TAG 2021

Stephen Harrison previews NASH-TAG 2021, the pre-eminent NASH drug development meeting, which will take place from March 10-12

The Newer Diabetes Drugs and Patients with NASH

S2-E7 – The Newer Diabetes Drugs and Patients with NASH

Jörn Schattenberg and Fatty Liver Foundation President Wayne Eskridge join Louise and Roger to consider the current and future roles that GLP-1 receptor agonists like semaglutide and SGLT-2 inhibitors like Jardiance in treating NASH patients.

Stay In Touch with Surfing NASH

Stay In Touch
  • Name
  • Email & NPI
  • Country
  • Institution & Profession